TargetBeta
STEAP1
STEAP family member 1 · also PRSS24, STEAP · Serine proteases
4 programs in company-led studies act on STEAP1, from 4 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| xaluritamigrule | Amgen | phase 3 | 77 running | CD3E | NCIt |
| Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969 | AbbVie | phase 1 | 11 running | FOLH1 | the company's pipeline |
| Anti-STEAP1 Antibody-drug Conjugate ADRX-0405rule | Adcentrx Therapeutics | phase 1 | 11 running | – | NCIt |
| HLX3902 | Fosun Pharma | phase 1 | 11 running | CD28, CD3E | the company's pipeline |
Conditions their studies are in
- Prostatic Neoplasms, 2 programs
- Sarcoma, Ewing, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 17, 2027xaluritamig · Amgen · phase 3 · NCT06613100
- May 2027Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969 · AbbVie · phase 1 · NCT06318273
- Jun 29, 2027HLX3902 · Fosun Pharma · phase 1 · NCT07533708
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.